Abstract 6498: MEK inhibitor mirdametinib suppresses MAP kinase pathway activity and inhibits tumor growth in atypical teratoid/rhabdoid tumorsYiming Deng, Eric H. Raabe, Tyler Findlay et al.|Cancer Research|2024Cited by 1
ATRT-17. INHIBITING THE MAP KINASE PATHWAY WITH MEK INHIBITOR MIRDAMETINIB SUPPRESSES CANCER GROWTH IN ATYPICAL TERATOID/RHABDOID TUMORSYiming Deng, Eric H. Raabe, Anupa Geethadevi et al.|Neuro-Oncology|2024Cited by 1